Targeted Therapies for Childhood ALL
written December 2010-January 2011 by Patty Feist, MS Biochemistry
Current therapies for childhood ALL claim an 85% overall survival rate. [Update 2012: An article by S. Hunger et al reports the survival rate of COG trials at the end of 2005 is 90.4%. The 85% value is from the Targeting paediatric acute lymphoblastic leukaemia 2010 article.] This is significantly better than the 10% survival rates in the 1960s or the "no survival" rate in the first part of the twentieth century. But the current therapies come with a price, as they are (almost) all "anti-neoplastic", meaning that they kill all dividing cells in the body. Since cancer cells divide more often than most other cells, they are more likely to be killed. But other dividing cells are killed too, leaving the children immunosuppressed, fatigued, plagued with mouth sores and gastrointestinal problems, hairless. The chemotherapies are toxic in other ways too, potentially leading to short and long term effects including cardiac issues, neuropathies, bone loss, avascular necrosis, learning issues, secondary cancers, and more. Some children have radiation in their treatment, which leads to another set of possible short and long term issues.
My son was diagnosed in 1997. I read his treatment plan and cringed: How could we pour all these toxic chemicals into his body for over 3 years? It was surreal watching the nurse administer the medication, then carefully disposing the syringes into toxic waste containers. A PhD student in a research lab working with an analog of one of his medications accidentally got some of it on herself and she thought she was in immediate medical compromise. But we were putting this drug in our son's veins!
It was my belief at that time — 1997 — that within a decade, the treatments for childhood ALL would advance to much less toxic therapies. Not so. Thirteen years later very little has changed in the treatment plans for ALL. In the standard of care treatment plans, the same toxic drugs are used as in the 1990s. Two additional toxic drugs, nelarabine and clofarabine, have been added to some trials. The only targeted drug is imatinib, which is only used for treatment in cases of the rare sub type, Ph+ childhood ALL. Because of MRD monitoring and the recognition of different sub types of the disease, treatment plans are now somewhat customized to each child's response to treatment and/or disease type. But the bottom line is, my son would have pretty much the same treatment today that he had in 1997, albeit probably it would be even more intense with toxic drugs. My prediction of treatment advances was wrong — and I am not happy about it.
That's why I perked up when I came across an article in the British Journal of Haematology. The title of the article is "Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development". (ref) This is a review article that covers targeted therapies for ALL that are either still in a research lab or actually out being studied in phase I or II clinical trials.
I was so interested in the targeted therapies article that I decided to write a "lay summary" of it, so that I could better understand the new strategies and keep track of the many new drugs (and their multiple names). I admit, this summary is written primarily for myself, but I am happy to share.
Lay summary of the journal article on targeted therapies
Reference: Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development. Alisa B. Lee-Sherick, Rachel M. A. Linger, Lia Gore, Amy K. Keating and Douglas K. Graham, British Journal of Haematology, Article first published online: 31 Aug 2010. Abstract.
When I hear of a new drug for ALL, I want to know everything about it: Is it another toxic drug? Is it a targeted therapy? What sub types of ALL is it likely to work best on? Is it or was it in a clinical trial? What are the side effects? Sometimes simply recognizing that a drug is new is confounded by the fact that they usually have several names. For instance, imatinib is also known as Gleevec, Glivec, STI 571, or imatinib mesilate. The targeted ALL therapies article lists scores of new drugs: How to keep them straight?
I created the table below by shortening the detailed information in Table I of the review article (reference just above), including only the drugs currently in trials for pediatric ALL. The majority of these targeted drugs trials are only for relapsed or refractory childhood ALL. And, the treatment plans that incorporate these targeted therapies are generally used in conjunction with one or more of the traditional cytotoxic chemotherapies.
Click on the "mode of action" link to jump to a description of how the drug works and clinical trials.
|mode of action||name of drugs||use in childhood ALL|
|BCR-ABL1 tyrosine kinase inhibition||Imatinib (STI571); Dasatinib (BMS-354825); Nilotinib (AMN107)||in trials (Ph+ ALL)|
|FLT3 receptor tyrosine kinase inhibition||Lestaurtanib (CEP-701); Midostaurin (PKC-412)||in trials (MLL-rearranged ALL, some T-cell ALLs, and high hyperdiploid ALL)|
|mTOR kinase inhibitors||Rapamycin (Sirolimus); Temsirolimus (CCI-779)||currently in phase I relapsed ALL trials|
|aurora kinase inhibitors||MLN8237||phase I/II relapsed ALL trials (currently closed)|
|multi-kinase inhibitors||Sorafenib (BAY439006)||phase I/II relapsed ALL trials|
|proteasome inhibitors||Bortezomib (PS-341)||phase I/II relapsed ALL trials|
|Farnesyltransferase inhibitors||Tipifarnib||was in trials, is not currently in trials|
|BCL2 antagonists||Obatoclax (GX 15-070)||phase I relapsed ALL trial|
|Histone deacetylase inhibitors||vorinostat (SAHA)||phase II relapsed ALL|
|DNA methyltransferase inhibitors||Decitabine||phase I/II relapsed ALL trials|
|CD Marker Antibodies||Rituximab; Epratuzimab; Alemtuzumab||phase I/II relapsed ALL trials|
|Conjugated CD Marker Antibodies||CAT8015 (HA22) DT2219ARL BU-12||phase I relapsed ALL trial|
|Other Stategies||(several)||(not yet in trials)|
Clinical trials: to find a clinical trial for a particular drug for childhood ALL, first go to the NCI clinical trials search page. Choose acute lymphoblastic leukemia, child; choose trial/treatment type "treatment"; then click on "choose from list" next to the drug button. After you have entered the drug of choice, go to the bottom of the page and click on the red search button. For information on the phases of trials, go to the ped-onc resource center.
Phosphorus has many roles in cells. For instance, it is part of the backbone of DNA, it supplies energy, and it activates proteins that serve as enzymes to catalyze cellular reactions. Activation of an enzyme is a way to control what happens in a cell, in the case we are interested in (cancer), it controls whether or not a cell dies.
Cell processes are usually pathways: one molecule affects another, which affects another, and another, and so on until the final outcome. Many factors feed into each pathway in a complex, convoluted maze of on/off switches (at least, it seems so to the layman!). The article has a great graphic of many of the pathways to cell death that have been studied with the "targeted" molecules noted; if you are interested, I suggest you get a copy of the full article, since I cannot reproduce it here for copyright reasons.
A kinase is an enzyme (in this case a protein) that facilitates the transfer of a phosphate group, usually from ATP (adenosine triphosphate) to a substrate. This transfer changes the form of the substrate and signals a cellular event to happen or not to happen. (Note: this is a very brief description: it's a lot more complicated than the previous two sentences!) There are over 500 kinases in humans, serving often as signals in various cell pathways. The ones applicable to ALL targeted therapies are described briefly below.
Philadelphia positive, or Ph+, ALL is characterized by the transposition of a specific part of chromosome 9 (q34, ABL1) and part of chromosome 22 (q11, BCR). This leads to a "fusion gene" that causes production of an incorrect form of tyrosine kinase protein called BCR-ABL1 TK, a form that cannot be regulated via normal cell pathways. In this case, the unregulated kinase eventually causes a stop in the normal process of cell death through apoptosis. No cell death, and it's a cancer cell.
The BCR-ABL1 TK needs to bind to ATP to work, and clever scientists designed a small molecule now called imatinib to compete for the ATP binding site that the mutant kinase requires to be active. Thus, the imatinib prevents the BCR-ABL1 TK from being active and the cell dies, as it is supposed to. Imatinib has an effect on cells that have BCR-ABL1 TK, but it has very little effect on the rest of the cells in the body, because they do not have the mutated tyrosine kinase, BCR-ABL 1, and thus imatinib is a targeted therapy.
Some patients' cancers become resistant to imatinib. Second generation tyrosine kinase inhibitors have been developed to overcome this problem; dasatinib and nilotinib are examples of newer tyrosine kinase inhibitors currently in clinical trials. Preclinical in vitro studies showed that nilotinib (AMN107) is more potent than imatinib against CML cells by a factor of 20 to 50. (2006 reference.)
BCR-ABL1 tyrosine kinase inhibitors are currently used in conjunction with chemotherapy in clinical trials for Ph+ ALL. Only a very small percentage of childhood ALLs are Ph+. Still, this is a very important and successful targeted therapy, if only for a specific sub set.
- Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in Children. Trial information. Phase II, III (active 2010)
- Phase III Study of Dasatinib in Combination With Intensified Chemotherapy in Young Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Trial information. (active 2010) COG-AALL0622
- A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib. Trial information. (active 2010)
- Decitabine, Vorinostat, and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma That Has Relapsed or Not Responded to Treatment. Trial information. (active 2010)
- First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL. Trial information. Phast II. (active 2010)
- Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+). Trial information. (not yet active 2010)
- Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders. Trial information. (active 2010)
- A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL). Trial information. (active 2010)
Another tyrosine kinase implicated in ALL is "FLT3 receptor tyrosine kinase" (FL stands for Fms-like). In some types of ALL, the FLT3 receptor tyrosine kinase is highly expressed and the cell grows out of control. One inhibitor of FLT-3 TK is the small molecule lestaurtinib (COP-701), which in culture has been shown to cause death of ALL cells that express high levels of FLT3. Another FLT3TK inhibitor in the pipeline is midostaurin (PKS-412).
MLL-rearranged infant ALL is one sub type of ALL that often highly expresses FLT3. Some T-cell ALLs and high hyperdiploid ALL also highly express FLT3. (reference)
- Phase III Partially Randomized Study of Risk-Directed Therapy Comprising a Modified P9407 Chemotherapy Backbone With or Without Lestaurtinib in Infants With Newly Diagnosed Acute Lymphoblastic Leukemia. Trial information. (COG-AALL0631, active 2010)
- A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia. Trial information. Phase I, II. For MLL-rearranged ALL. Ages 3 months to 18 years. (Active 2010)
Some pediatric ALLs have an "upregulated" (meaning, turned on) pathway to increased cell survival called the the PI3K/AKT pathway. One control point in this pathway is called the "mammalian target of rapamycin", or mTOR for short. mTOR is a serine/threonine protein kinase. Rapamycin inhibits mTOR and causes a halt in cell growth. Temsirolimus is a second generation mTOR inhibitor; both rapamycin and temsirolimus are in early clinical trials for pediatric ALL. Everolimus and ridaforolimus are later generation mTOR inhibitors that might be tried against ALL. In patient samples of pre-B cells, everolimus (RAD001) synergized with chemotherapy, radiation, and proteasome inhibitors to kill the cells. (Article, 10/2010.)
Note: Rapamycin and mTOR is the subject of a Scientific American article on aging, A New Path to Longevity, Jan 2012.
- Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma. Trial information. Phase II. (active 2010, patients under 25)
- Phase I Study of Sirolimus in Pediatric Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin's Lymphoma. Trial information. (active 2010, patients under 21)
- Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL). Trial information. Phase I, 21 and under. (active 2010)
- Rapamycin in Relapsed Acute Lymphoblastic Leukemia. Trial information. Phase not specified, ages 1 and over. (active 2010)
Some leukemia cell lines (meaning, leukemia cells maintained in culture) show increased expression of Aurora serine/threonine kinases, kinases that regulate cell proliferation through control of mitosis, a step in cell division. MLN8237 is a small molecule that inhibits Aurora A kinase. It is currently in clinical trials for relapsed/refractory childhood leukemias. In 2010, it showed promise in adult cancers. In the Pediatric Preclinical Testing Program, it shows promise against ALL. Abstract.
Aurora kinase inhibitiors have been tested both in culture and in humans, and inhibit not only Aurora kinases, but also ABL 1 TK and FLT3 kinases.
- Phase I/II Study of Aurora A Kinase Inhibitor MLN8237 in Pediatric Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia (Acute Lymphoblastic Leukemia Closed to Accrual as of 02/18/10). Trial information. (COG-ADVL0812)
- Phase II Study of Aurora A Kinase Inhibitor MLN8237 in Pediatric Patients With Recurrent or Refractory Solid Tumors or Leukemia. Trial information. (not yet active 2010; COG-ADVL0921)
As mentioned above in the Aurora kinase section, some inhibitors target more than one kinase. Sorafenib is a multi-kinase inhibitor that works in several different points in a pre-survival pathway. There is some promise that this drug will overcome the acquired resistance that has been observed for selective tyrosine kinase inhibitors (like imatinib). Sorafenib has also been found to increase levels of a tumor necrosis factor. Sorafenib is currently in phase I trials for relapsed/refractory pediatric ALL.
- Phase I/II Study of Sorafenib in Pediatric Patients With Relapsed or Refractory Solid Tumors or Leukemia. Trial information. (active 2010; COG-ADVL0413)
- Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies. Trial information. (active 2010; 31 and under)
Kinases and even enzymes are not the only targets being studied.
Proteasomes are large protein complexes that help regulate cell growth/death by selectively degrading certain other proteins. When they destroy a protein called I-kappa-B, the transcription factor NFKB1 goes to the cell nucleus and anti-apototic proteins are activated. In pediatric ALL, NFKB1 is "constitutively" active, and this leads to a stoppage of apoptosis/cell death (no cell death = cancer). Bortezomib is a specific proteasome inhibitor that has shown promise in clinical trials of adult leukemias and is now in clinical trials of pediatric leukemias. (reference)
- Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL). Trial information. (phase I/II, active 2010, ages 1-21)
- Phase II Pilot Study of Bortezomib in Combination With Intensive Reinduction Chemotherapy in Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma. Trial information. (COG-AALL07P1, active 2010, ages 1-31)
The protein RAS is activated in several childhood ALLs; this leads to pro-survival of the cell. RAS is first produced in the cell without a group called "farnesyl isoprene", and it requires the enzyme farnesyltransferase to be activated. Farnesyltransferase inhibitors thus provide a targeted therapy for childhood ALL. Tipifarnib was found to moderately decrease farnesyltransferase in phase I clinical trials (reference, reference 2); there is some data that suggest that T-cell leukemias are more sensitive to it than B-cell leukemias. It is not currently in pediatric ALL trials.
Targeting apoptotic pathways
Programmed cell death occurs through apoptosis, a word that derives from the Greek "dropping off" or "falling off" as in leaves from a tree. One group of regulatory proteins that helps to control apoptosis is the Bcl-2 family. The pan-Bcl-2 small molecule inhibitor Obatoclax is currently in phase I trials on childhood ALL.
ABT-737 is another small molecule that inhibits the Bcl-2 family of proteins and it has shown promise in pediatric ALL cell lines with the MLL rearrangement (reference). (In the referenced article, the authors state that significant Bcl-2 expression was detected in all infant leukemia cells investigated.) When used in combination with common drugs administered in ALL therapy, ABT-737 has the ability to enhance the combined toxicity of these drugs against the leukaemia cells in vitro and in vivo. (reference.)
- Phase I Study of Obatoclax Mesylate in Combination With Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Pediatric Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia. Trial information. (active 2010; 6 months to 21 years; COG-ADVL0816)
Histone deacetylases (HDAC) are enzymes that remove acetyl groups from histones in nucleosomes and, through a complex pathway, stop the transcription of control proteins (e.g., tumor suppressor genes). With no control, the cell is a cancer cell. HDACs are inhibited by histone deacetylase inhibitors (HDACi). In leukemia cells (but not normal cells), HDACi's also increase transcription of apoptotic proteins (a good thing). The HDACi vorinostat is currently in clinical trials in combination with decitabine (next category).
In ALL, it has been found that certain regions of the DNA are overly covered with methyl groups. The regions of interest are areas that control cell growth, and the "hypermethylation" leads to the cell growing out of control. DNA methyltransferase inhibitors prevent this hypermethylation. 5-Azacytidine (azacitadine) is a DNA methyltransferase inhibitor that has been assessed in adult malignancies; the more potent 5-aza-2'-deoxycytidine (decitabine) is currently in clinical trials fro childhood ALL. In one case, a pediatric patient with multiply relapsed ALL achieved remission with decitabine.
According to two new papers (this is not in the review article), aberrant DNA methylation occurs in the majority of infant ALL cases with the MLL rearrangement, so maybe DNA methylase inhibitors will prove useful for MLL infant ALL. (2009 article; 2010 article)
- Decitabine, Vorinostat, and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma That Has Relapsed or Not Responded to Treatment. Trial information. (active 2010)
Non-oncogenic surface targets
Parents of children with ALL may be familiar with the term "CD surface markers", which are proteins on the cell surface (ALL cell types on ped-onc site). For instance, pre-B ALL sub types express CD19 and CD10, while T-cell ALL sub types express CD2, CD7, CD5, or CD3. (CD stands for "cluster of differentiation".) Researchers have found that monoclonal antibodies (mAb) that target specific B-cell CD markers kill the cells that have the markers, although they are not sure as to the exact mechanism. CD22 is expressed in over 95% of pre-B ALLs; epratuzumab is an anti-CD22 mAb (reference); Rituximab is an anti-CD20 mAb. Other mABs in the pipeline include alemtuzumab and CMC-544.
- Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia. Trial information. (active 2010; phase I, II, ages 16 and over).
- Phase II Pilot Study of Epratuzumab Alone and in Combination With Re-Induction Combination Chemotherapy in Pediatric Patients With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (Part A closed to accrual as of 10/30/06). Trial information. (COG-ADVL04P2, phase II, active 2010)
- Phase II Study of Rituximab as Upfront Window Therapy Before Chemotherapy in Pediatric Patients With Mature B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia. Trial information. (active 2010, phase II, under age 19)
- Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage. Trial information. (phase II; active 2010; all ages)
- Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia. Trial information. (active 2010; ages 1-30)
Monoclonal antibodies (mAbs) alone do not always cause cell death (exceptions are "unconjugated" antibodies; one is epratuzumab). However, a mAb can be connected to a cell-killing (cytotoxic) agent, such as an antibiotic, a bacterial exotoxin, or a radioisotope to form a "conjugated mAb". The conjugated mAb can then snuggle up right next to the targeted cell and deliver the cytotoxic agent. I first learned of this approach in the late 1990s (see the bottom of my decade-old "good news" page).
The following are conjugated CD marker antibodies in the pipeline.
- anti-CD 22: CD 22 mAb conjugated to the antibiotic calicheamicin, named CMC-544 (inotuzumab ozogamicin)
- anti-CD 19: CD 19 mAb conjugated to the antibiotic calicheamicin (reference)
- anti-CD22 mAb linked to the pseudomonas exotoxin PE38, named CAT 3888 (BL22).
- anti-CD22 mAb linked to the Pseudomonas exotoxin PE38, named CAT 8015 (HA22) (second generation).
- anti-CD22 immunotoxin HA22 (CAT-8015). 2010: Currently tested in in vitro cell lines, . . . "HA22, at concentrations achievable in patients, is highly cytotoxic to B-lineage ALL cells. These results provide a strong rationale for clinical testing of this agent in children with drug-resistant ALL and offers the potential to reduce morbidities of treatment while improving outcome." Francis Mussai et al., British Journal of Haematology, June 10, 2010. Abstract.
- Phase I trial for children/adolescents with refractory ALL. CAT-8015 proves promising in a child who failed 3rd remission. Trial information. (see this NIH page for more information).
- dual anti-CD22 and anti-CD19 linked to the immunotoxin deglycosylated ricin-A (RFB4-dgA and HD37-dgA), named Combotox.
- DT2219 ARL (anti-CD19/CD22 bispecific ligand-directed toxin)
- BU-12 (yttrium Y 90 anti-CD19 monoclonal antibody BU12)
- CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL). Trial information. (phase I; active 2010; ages 16 and over).
- CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma. Trial information. (active 2010; phase I; 6 months to 25 years)
- Phase I Study of Anti-CD19/CD22 Bispecific Ligand-Directed Toxin DT2219ARL in Patients With Relapsed or Refractory CD19(+) and CD22(+) B-Lineage Leukemia or Lymphoma. Trial information. (active 2010; phase I; age over 12)
Finally, I am listing some therapies that were discussed in the article but do not yet have drugs in clinical trials. TAM tyrosine kinase inhibitors are studied still in cell lines (in vitro), hopefully these will be useful for childhood leukemias (reference). Gamma secretase inhibitors show promise for T-cell ALL (NOTCH mutations). (NOTCH 1: Oncogene and Achilles' Heel in T-ALL. A good article on possible new ways to treat T-cell ALL on the St. Judes Cure For Kids website. Free registration is required.) Securin, a protein involved in cell division, is a target for inhibition. Others: heat shock protein inhibitors (tanespimycin, alvespinycin, 17-allylaminogeldanamycin), TRAIL receptor agonists (lexatumumab, mapatumumab, survivin inhibitors, JAK tyrosine kinase inhibition (Down syndrome and Latino/Hispanic patients), Survivin inhibitors, BiTE antibodies, Chimeric T-cell receptors.
As presented in the article, there are quite a few promising targeted therapies in the pipeline for use in treating childhood ALL. So far, no single one has stood out as the cureall for all types of ALL, but it is encouraging that progress is being made, and perhaps one of these up-and-coming treatments will make a big difference in all subtypes of ALL.
As promising as they are, the targeted therapies present challenges. For instance, imatinib has been in treatment plans for a long time, and patients do build up a resistance to this drug. For instance, other pathways in the cell can upregulate to compensate for the inhibited protein. A problem with cell surface protein targeting is the likelihood of altered cell surface receptor expression after the therapy ends, perhaps leading to the selection of a population of cells with high resistance.
Another issue is that the therapies are not absolutely targeted therapies, meaning that they do affect some normal cells in the body. Thus, side effects both on treatment and years after treatment might still be an issue. Such late effects are not anticipated, but only time will tell.
In the conclusion of the article is the statement "Despite the possible secondary effects of targeted therapies, these novel treatments have great potential." They continue on to state that childhood ALL is a "heterogeneous group of cancers . . . [allowing] development of novel treatments based on the exact specificaitons of the disease, such as treating pre-B cell leukemia with an anti-CD22 mAb, treating MLL-rearranged leukemia with a FLT3 inhibitor, or treating T-cell ALL with a gamma-secretase inhibitor." Thus, someday a child's treatment will be specifically targeted, according to the sub type of the cancer.
On a personal level, I am both encouraged and discouraged. Encouraged because a good number of strategies for non-toxic therapies are in the works for childhood ALL. Discouraged because these treatments will not soon rid childhood ALL treatment plans of toxic therapies—currently, in clinical trials, the therapies are still being used in conjunction with conventional chemotherapy regimens. I was hoping for a "magic bullet". I was hoping that soon a newly diagnosed child would swallow a few pills, go home, and be leukemia free.
Hopefully the day will soon come where the treatment for childhood ALL will not be as harsh as it is today. A newly diagnosed child's leukemia cells would be tested immediately, the exact specification of the disease would be determined, and a non-toxic treatment plan initiated that would give a 100% cure rate with no long term effects.
We can hope. I for one am so glad to know that the researchers are indeed working towards this goal.
The first article is the main reference, others are included for those interested in looking further into specific topics.
Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development. Alisa B. Lee-Sherick, Rachel M. A. Linger, Lia Gore, Amy K. Keating and Douglas K. Graham, British Journal of Haematology, Article first published online: 31 Aug 2010. Abstract.
Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR–ABL-positive acute lymphoblastic leukemia. S Mizuta et al., Leukemia (2011) 25, 41–47; published online 14 October 2010. Abstract.
Philadelphia chromosome-positive acute lymphoblastic leukemia in children: new and emerging treatment options. Kirk R Schultz et al., Expert Review of Hematology December 2010, Vol. 3, No. 6, Pages 731-742. Abstract. "Although targeted tyrosine kinase inhibitors (TKIs) have limited activity against Ph+ ALL as a single agent, they have been evaluated in combination with chemotherapy with promising results. The early results of Children's Oncology Group trial AALL0031 have shown 88% 3-year event-free survival for Ph+ patients treated with intensive chemotherapy plus continuous-dosing imatinib. This suggests that chemotherapy plus TKIs may be the initial treatment of choice for Ph+ ALL in children. However, the numbers are small in this trial and confirmatory results are not yet available from the European Intergroup Study on Post Induction Treatment of Philadelphia Positive Acute Lymphoblastic Leukaemia with Imatinib trial. Additional issues include determining the most effective TKI (imatinib, dasatinib or nilotinib) and the most effective, least toxic chemotherapy backbone. The experience of adding a targeted agent such as a TKI to the standard chemotherapy regimen suggests that this strategy might be applied to other ALL subtypes to achieve both increased efficacy and decreased toxicity."
New articles that were published after the review article
UNC569, a novel small molecule Mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo.Christoph S et al., Mol Cancer Ther, epub 2013 Aug 30. Abstract.
BCR-ABL1 molecular remission after 90 Y-epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B-ALL: proof of principle. Chevallier P et al., Eur J Haematol, epub 2013 Aug 8. Abstract.
AMPK inhibition enhances apoptosis in MLL-rearranged pediatric B-acute lymphoblastic leukemia cells. B Accordi et al., Leukemia (2013) 27, 1019–1027. Abstract.
Inotuzumab ozogamicin, an anti-CD22—calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Hagop Kantarjian et al., The Lancet Oncology, epub, 21 February 2012. Abstract.
JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia. Fatih M Uckun et al., Expert Review of Anticancer Therapy January 2011, Vol. 11, No. 1, Pages 37-48. Abstract.
New Strategies in Acute Lymphoblastic Leukemia: Translating Advances in Genomics into Clinical Practice. Charles G Mullighan, Clin Cancer Res, Published OnlineFirst December 13, 2010. Abstract. "Deletion or sequence mutation of the lymphoid transcription factor gene IKZF1 (IKAROS) is associated is associated with a high rate of leukemic relapse...rearrangement of CRLF2 and activating mutations of Janus kinases (JAK1 and JAK2). JAK inhibitor therapy is under investigation in children with relapsed and refractory malignancies, including leukemia." Oral JAK inhibitor INCB18424.
Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. C Evangelisti et al., Leukemia, 18 February 2011. Abstract. The authors used different-strategy inhibitors of mTOR and showed success in inhibiting T-cell leukemia cells in culture and samples from patients. ". . . inhibition of mTORC1 by rapamycin has only modest effects in T-cell acute lymphoblastic leukemia (T-ALL) . . . . Unlike rapamycin, we found a marked inhibition of mRNA translation in T-ALL cell lines treated with active-site mTOR inhibitors. The inhibitors strongly synergized with both vincristine and the Bcl-2 inhibitor, ABT-263." (The authors did not put the name of the mTOR1/2 inhibitors in the abstract and full text was not available for this online first article 3/11.)
Improving outcomes for high-risk ALL: Translating new discoveries into clinical care. Stephen P. Hunger et al., Pediatric Blood & Cancer, first published online: 15 FEB 2011. Abstract. The article addresses the issue of high risk ALL, ALL that is resistant to current chemotherapy regimens, regimens that are limited by toxicity. "High-resolution genomic profiling of genetic alterations and gene expression has revolutionized our understanding of the genetic basis of ALL, and has identified several alterations associated with poor outcome, including mutations of the lymphoid transcription factor gene IKZF1 (IKAROS), activating mutations of Janus kinases, and rearrangement of the lymphoid cytokine receptor gene CRLF2. These data indicated that the genetic basis of HR-ALL is multifactorial, and have also provided a new potential therapeutic option directed at JAK inhibition."